199391-75-8

Basic information

• Product Name: 2,3-bis(2-hydroxyethyl)phenol
• CAS NO: 199391-75-8
• Molecular Formula: C₁₀H₁₄O₃
• Molecular Weight: 182.2164
• Mol File: 199391-75-8.mol

Chemical Properties

• Boiling Point: 367.5°C at 760 mmHg
• Flash Point: 183°C
• Density: 1.226g/cm³
• Vapor Pressure: 4.75E-06mmHg at 25°C
• Refractive Index: 1.592
• CAS DataBase Reference: 2,3-bis(2-hydroxyethyl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-bis(2-hydroxyethyl)phenol(199391-75-8)
• EPA Substance Registry System: 2,3-bis(2-hydroxyethyl)phenol(199391-75-8)

Safety Data

• Hazardous Substances Data: 199391-75-8(Hazardous Substances Data)

Usage

Uses

Used in Plastics Industry:
2,3-bis(2-hydroxyethyl)phenol is used as a key component in the production of epoxy resins for its ability to enhance the durability and heat resistance of plastic materials, making them suitable for a wide range of applications.
Used in Adhesives Industry:
In the adhesives industry, 2,3-bis(2-hydroxyethyl)phenol is used as a raw material for creating epoxy resins that provide strong bonding properties and chemical resistance, which are essential for various manufacturing processes.
Used in Coatings Industry:
2,3-bis(2-hydroxyethyl)phenol is utilized in the formulation of coatings to improve their adhesion, corrosion resistance, and overall performance, particularly in environments exposed to high temperatures and chemicals.
Used in Flame Retardants Production:
2,3-bis(2-hydroxyethyl)phenol is used as a starting material in the production of flame retardants, which are crucial for imparting fire-resistant properties to various materials, thereby enhancing safety standards in different industries.
Used in Pharmaceutical Synthesis:
2,3-bis(2-hydroxyethyl)phenol is employed as an intermediate in the synthesis of certain pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
However, it is important to note that there is ongoing research into the potential health and environmental impacts of 2,3-bis(2-hydroxyethyl)phenol, particularly concerning its endocrine-disrupting properties and environmental persistence. As a result, its use may be subject to regulatory scrutiny and potential restrictions in the future.

Upstream product

• 90-15-3 α-naphthol 
• 27673-48-9 5,8-dihydro-1-naphthol 
• 36192-01-5 5,8-dihydro-1-naphthyl benzyl ether 

Downstream Products

• 230642-83-8 C₁₇H₁₈O₄S 

Relevant articles and documents

Tasimelteon intermediate and preparation method thereof

The invention provides a tasimelteon intermediate and a preparation method thereof. The preparation method comprises the following steps: with a compound a as a raw material, reacting the compound a with benzyl bromide so as to obtain a compound I; then subjecting the compound I to a reaction under the action of a combined catalyst consisting of potassium osmate dihydrate, potassium carbonate, potassium ferricyanide, benzyltriethylammonium chloride and methane sulfonamide or a combined catalyst consisting of osmium tetroxide, potassium carbonate, potassium ferricyanide, benzyltriethylammonium chloride and methane sulfonamide so as to obtain a compound II; subjecting the compound II to an oxidation reaction under the action of sodium periodate or lead tetraacetate so as to obtain an intermediate compound III and carrying out a reduction reaction so as to obtain a compound IV; and subjecting the compound IV to a reduction reaction to remove a benzyl protective group so as to obtain a compound V, then reacting the compound V with p-toluene sulfonyl chloride, carrying out hydroxyl protection and then carrying out cyclization under the action of potassium carbonate so as to obtain the tasimelteon intermediate compound VI. The invention provides a novel process for preparation of the tasimelteon intermediate; and the prepared tasimelteon intermediate has good purity and high quality and is applicable to industrial production.

Gram-Scale Synthesis of Chiral Cyclopropane-Containing Drugs and Drug Precursors with Engineered Myoglobin Catalysts Featuring Complementary Stereoselectivity

Engineered hemoproteins have recently emerged as promising systems for promoting asymmetric cyclopropanations, but variants featuring predictable, complementary stereoselectivity in these reactions have remained elusive. In this study, a rationally driven strategy was implemented and applied to engineer myoglobin variants capable of providing access to 1-carboxy-2-aryl-cyclopropanes with high trans-(1R,2R) selectivity and catalytic activity. The stereoselectivity of these cyclopropanation biocatalysts complements that of trans-(1S,2S)-selective variants developed here and previously. In combination with whole-cell biotransformations, these stereocomplementary biocatalysts enabled the multigram synthesis of the chiral cyclopropane core of four drugs (Tranylcypromine, Tasimelteon, Ticagrelor, and a TRPV1 inhibitor) in high yield and with excellent diastereo- and enantioselectivity (98–99.9% de; 96–99.9% ee). These biocatalytic strategies outperform currently available methods to produce these drugs.

ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C-R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.